Effect of polymer nature and architecture on body fate

合理开发有效的给药系统需要了解药物载体与生物系统之间复杂的相互作用。然而，由于细胞培养中可用的许多分析技术不能在体内应用，关于聚合物药物载体的详细命运的知识仍然有限。在这里，我们着手研究、描述和理解控制大分子工程在生物环境中的作用，具体目标是开发具有可控长度尺度和足够的身体分布的合成物体，作为靶向药物递送的聚合物载体。为了实现这一目标，建议开发具有不同性质的聚合物家族，例如电荷密度，构象结构或生物降解率，并使用非侵入性监测技术系统地研究它们在体内系统中的行为。我们提案中的创新源于我们个人实验室的两项最新进展：使用先进的偶联疗法，采用创新的受控聚合物合成策略和生物反应化学，赋予其独特的特性。一套新颖的非侵入性成像技术提供独特的身体命运信息。小动物的ESR、MRI和荧光技术的可用性可以提供独特的信息。这个ERA网络是一个集中的卓越集群，汇集了来自菲利普亲王研究中心（CIPF，西班牙）和马丁-路德-大学Halle-Wittenberg（德国）的具有独特成像技术的研究小组在先进纳米结合治疗方面的国际竞争力的研究小组。era -化学小组的领导通过在主题领域的高影响力出版物展示了专业知识，并首次将这些技能作为一个团队聚集在一起，形成了一个强大的新的跨学科和好奇心驱动的联盟。

The rational development of an effective drug delivery system requires the understanding of the complex interplay between the drug carrier and the biological system. However, the knowledge concerning the detailed fate of polymeric drug carriers is still limited due to the fact that many analytical techniques available in cell cultures cannot be applied in vivo. Here we set out to investigate, characterise and understand the role of controlled macromolecule engineering in biological settings with the specific aim to develop synthetic objects with controllable length-scales and adequate body distribution to be used as polymeric carriers for targeted drug delivery. In order to achieve this goal, it is proposed to develop a family of polymers with different properties, such as, charge density, conformational structure or biodegradability rate and to use non-invasive monitoring techniques to study, systematically, their behaviour in in vivo systems.The innovations in our proposal stem from two recent advances in our individual laboratories: Use of Advanced Conjugate Therapeutics, with innovative controlled polymer synthesis strategies and bioresponsive chemistries to give their unique properties. A novel set of non-invasive imaging techniques providing unique information on body fate. The availability of ESR, MRI and Fluorescence techniques for small animals can provide unique information. This ERA network is a focused cluster of excellence that brings together internationally competitive research groups on advanced nanoconjugate therapeutics from the Prince Felipe Research Center (CIPF, Spain), and from Martin-Luther-University Halle-Wittenberg (Germany), a research group with unique imaging technologies. ERA-chemistry group leaders have demonstrated expertise through high impact publications in the thematic areas and bring these skills together for the first time as a team to form a powerful new interdisciplinary and curiosity-driven consortium.